TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02471248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Robot with Power Assistance
Description: Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion.
Study: NCT00166010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
Study: NCT01513096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride
Description: itopride, 10mg, twice per day, for 1 day
Study: NCT02296073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam 3～5μg/kg•min for maintenance of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
Study: NCT05111496

Intervention type: RADIATION
Intervention: Gafchromic film
Description: Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
Study: NCT00387387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX 6
Description: FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
Study: NCT02296073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
Study: NCT03311607

Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
Study: NCT00773760

Intervention type: OTHER
Intervention: SNP genotyping
Description: Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
Study: NCT04204915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
Study: NCT02099916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropins plus DHEA
Description: Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropins plus DHEA
Description: Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Study: NCT03271151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cymbalta
Description: Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to compare outcomes against Duloxetine
Study: NCT02296073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment
Description: Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment
Description: Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment
Description: Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment
Description: Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
Study: NCT04977557

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thiamine
Description: Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
Study: NCT02954250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
Study: NCT01716390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink that contains plant stanols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Study: NCT03980977

Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G).
Study: NCT02118506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical practice
Description: The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental and physical practice
Description: The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.
Study: NCT04087044

Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Rotational Head Impulse Test ( crHIT)-Vertical
Description: 1. Oculo-Motility and Positional Testing,~2. Caloric Testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Rotational Head Impulse Test ( crHIT)-Vertical
Description: 1. Oculo-Motility and Positional Testing,~2. Caloric Testing
Study: NCT00630513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: 3 days regimen with Ertapenem (1 g/day i.v.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-Sulbactam
Description: 3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
Study: NCT02209987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5745 SC
Description: GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5745 IV
Description: GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
Study: NCT02960932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound scanner
Description: Ultrasound scanner used to the SSI technical reproducibility.
Study: NCT02421328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP first (Fisher & Paykel Healthcare)
Description: Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC first (Fisher & Paykel Healthcare)
Description: Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
Study: NCT03484923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously
Study: NCT01691911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote preconditioning
Description: Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
Study: NCT04252664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir placebo
Description: RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study: NCT02371889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Max therapeutic dose of 200mg/day

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
Study: NCT03980977

Intervention type: OTHER
Group type: OTHER
Intervention: tumor biopsy
Description: an additional tumor sample will be taken during programmed diagnostic procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: blood sample will be taken for biological collection
Study: NCT03208127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Direct Acting Antiviral tablet
Description: HCV Treatment for 12 Weeks
Study: NCT03491267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: The study team will treat skin with topical retinoic acid
Study: NCT01254214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tMBSR
Description: MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
Study: NCT03491267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: The study team treat skin with a surface laser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: No drug will be given

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: No laser treatment will be given
Study: NCT00961649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study: NCT01497730

Intervention type: DEVICE
Intervention: Total Knee Replacement
Description: Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.

Intervention type: DEVICE
Intervention: Total Knee Replacement
Description: Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.

Intervention type: DEVICE
Intervention: Total Knee Replacement
Description: Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.

Intervention type: DEVICE
Intervention: Total Knee Replacement
Description: Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.
Study: NCT00819884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral suspension
Study: NCT03469960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg every 6 weeks
Study: NCT00961649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%
Study: NCT03469960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg every 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks
Study: NCT02852837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
Study: NCT03193580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Conventional tDCS
Description: tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
Study: NCT00961649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Inactive ingredients used as placebo